High-quality cardiac safety screening services, including GLP hERG and CiPA assays
The cardiac safety screening assays we offer include:
Specialist GLP screening services against hERG using the conventional whole-cell patch-clamp technique.
Generate GLP hERG data to support Investigational New Drug (IND) applications.
Measure the potential for test compounds to become trapped inside the hERG channel pore.
Provide an early assessment of potential off-target effects on cardiac ion channels by studying the effect of compounds on the CiPA ion channel panel.
Evaluate the effect of compounds on contractility and viability of human iPSC-derived cardiomyocytes using an impedance platform.
A powerful tool for safer and more efficient drug discovery.
Clinical QTc/QRS prediction using hiPSC derived cardiomyocytes.
Advantages of the hiPSC cardiomyocyte model.
Successfully detect between compounds with low, medium and high proarrhythmic risk profiles.
Assays for hERG, NaV1.5 and CaV1.2
Dynamic hERG assay.
Eliminate cardiac risk liability before lead development.
By working with us you benefit from:
Exceptional ion channel electrophysiology and drug discovery expertise.
A team of experienced cell biologists to create novel cell lines.
High quality, cost-effective compound screening.
Detailed characterisation of lead compounds in a range of high quality assays.
Translational services including confirmation of efficacy in stem cell and other phenotypic models.
Flexible approach that best suits your project and budget.
Rapid turn-around times, reporting and data interpretation by highly experienced ion channel scientists.
Our expertise in GLP hERG screening is demonstrated in the case study GLP hERG Assay Validation Following ICH E14/S7B 2022 Q&A Best Practice Guidelines.
Top: Example traces in vehicle, dofetilide and E-4031. Bottom: Corresponding IT plot. IC50 values generated were within 2-fold of the values reported in the ICH E14/S7B training material. Read more about GLP hERG assay validation.
Download the recording of this webinar to learn how an hiPSC-CM model can help provide clear decision-making data for your project team that can avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.
Recording includes presentations and Q&A:
Derek Leishman (VP Translational and Quantitative Toxicology, Eli Lilly and Company).
Steve Jenkinson (VP Drug Discovery and Safety, Metrion).
The HESI Cardiac Safety Committee present results from an international ion channel research study that assessed the variability of hERG data generated using automated patch clamp platforms (QPatch 48, Qube 384 and the SyncroPatch 384i) across four different labs.
Reliably evaluate the proarrhythmic and cardiotoxic liabilities of your compounds.